The JDRF is funding research efforts of ViaCyte to bring us closer to a T1D cure. ViaCyte is pioneering a combination product packaging stem cells that develop into insulin-producing cells. We speak with Dr. Julia Greenstein, Vice President for Cure Therapies at JDRF, to learn more about this promising T1D treatment.
- Join the e-newsletterFor Email Marketing you can trust.
Allies Voice's Recent Tweets